


PRODUCT INFORMATION



Vorasidenib

Item No. 28462

CAS Registry No.: 1644545-52-7
Formal Name: 6-(6-chloro-2-pyridinyl)-N²,N⁴-bis
[(1R)-2,2,2-trifluoro-1-methylethyl]-
1,3,5-triazine-2,4-diamine
Synonym: AG-881
MF: C₁₄H₁₃ClF₆N₆
FW: 414.7
Purity: ≥98%
UV/Vis.: λ_{max}: 218, 284 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Vorasidenib is supplied as a crystalline solid. A stock solution may be made by dissolving the vorasidenib in the solvent of choice, which should be purged with an inert gas. Vorasidenib is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of vorasidenib in these solvents is approximately 30 mg/ml.

Vorasidenib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, vorasidenib should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Vorasidenib has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Vorsidenib is an inhibitor of mutant isocitrate dehydrogenase (IDH; IC₅₀s = 31.9 and 31.7 nM for IDH1^{R132H} and IDH2^{R140Q}, respectively).¹ It also inhibits wild-type-IDH1^{R132H} and wild-type-IDH2^{R140Q} heterodimers (IC₅₀s = 4 and 251 nM, respectively).² Vorsidenib decreases the production of D-2-hydroxyglutarate (2-HG; Item Nos. 25895 | 11605) in TF-1 leukemia cells expressing IDH1^{R132H} or IDH2^{R140Q} (IC₅₀s = 3.2 and 14 nM, respectively). It reduces tumor growth in a TS603-IDH1^{R132H} mouse xenograft model when administered at a dose of 50 mg/kg.³

References

1. Ma, R. and Yun, C.-H. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2. *Biochem. Biophys. Res. Commun.* **503**(4), 2912-2917 (2018).
2. Yen, K., Konteatis, Z., Sui, Z., et al. AG-881, a brain penetrant, potent, pan-mutant IDH (mIDH) inhibitor for use in mIDH solid and hematologic malignancies. *AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics* **17**(Suppl. 1), (2017).
3. Nicolay, B., Narayanaswamy, R., Amatangelo, M.D., et al. Exth-34. Combined use of pan-IDH mutant inhibitor AG-881 with radiation therapy shows added benefit in an orthotopic IDH1 mutant glioma model *in vivo*. *Neuro. Oncol.* **19**(Suppl. 6), vi79 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/06/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM